Integrin αvβ3 and LHRH Receptor Double Directed Nano-Analogue Effective Against Ovarian Cancer in Mice Model
Na Qi,Xiantai Zhou,Ningzhu Ma,Jianguo Zhang,Zhenlin Wang,Xin Zhang,Aimin Li
DOI: https://doi.org/10.2147/ijn.s442921
IF: 7.033
2024-03-29
International Journal of Nanomedicine
Abstract:Na Qi, 1, &ast Xiantai Zhou, 2, &ast Ningzhu Ma, 2 Jianguo Zhang, 2 Zhenlin Wang, 2 Xin Zhang, 1 Aimin Li 1 1 Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, People's Republic of China; 2 Department of Pharmacy, Guilin Medical University, Guilin, 541004, People's Republic of China &astThese authors contributed equally to this work Correspondence: Aimin Li; Xin Zhang, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, People's Republic of China, Email ; Introduction: The high mortality rate of malignant ovarian cancer is attributed to the absence of effective early diagnosis methods. The LHRH receptor is specifically overexpressed in most ovarian cancers, and the integrin αvβ 3 receptor is also overexpressed on the surface of ovarian cancer cells. In this study, we designed LHRH analogues (LHRHa)/RGD co-modified paclitaxel liposomes (LHRHa-RGD-LP-PTX) to target LHRH receptor-positive ovarian cancers more effectively and enhance the anti-ovarian cancer effects. Methods: LHRHa-RGD-LP-PTX liposomes were prepared using the thin film hydration method. The morphology, physicochemical properties, cellular uptake, and cell viability were assessed. Additionally, the cellular uptake mechanism of the modified liposomes was investigated using various endocytic inhibitors. The inhibitory effect of the formulations on tumor spheroids was observed under a microscope. The co-localization with lysosomes was visualized using confocal laser scanning microscopy (CLSM), and the in vivo tumor-targeting ability of the formulations was assessed using the IVIS fluorescent imaging system. Finally, the in vivo anti-tumor efficacy of the formulations was evaluated in the armpits of BALB/c nude mice. Results: The results indicated that LHRHa-RGD-LP-PTX significantly enhanced cellular uptake in A2780 cells, increased cytotoxicity, and hand a more potent inhibitory effect on tumor spheroids of A2780 cells. It also showed enhanced co-localization with endosomes or lysosome in A2780 cells, improved tumor-targeting capability, and demonstrated an enhanced anti-tumor effect in LHRHR-positive ovarian cancers. Conclusion: The designed LHRHa-RGD-LP-PTX liposomes significantly enhanced the tumor-targeting ability and therapeutic efficacy for LHRH receptor-positive ovarian cancers. Keywords: modified liposome, LHRHa, RGD, paclitaxel, ovarian cancer Graphical Ovarian cancer is one of the most lethal gynecological malignancies, difficult to diagnose early, and is characterized by a poor prognosis. 1,2 Currently, the treatment for ovarian cancer mainly involves surgery and platinum/taxane-based chemotherapy; however, the majority of patients experience recurrence months to years after diagnosis. 3,4 Generally, ovarian cancer is hormone-dependent. The expression level of the Luteinizing hormone-releasing hormone (LHRH) receptor is significantly increased in nearly 80% of human ovarian cancer cells, while its expression is minimal in most other healthy organs. 5,6 Physiologically, LHRH is synthesized in the hypothalamus and secreted from the pituitary. 6 Natural LHRH is unstable and rapidly degraded in vivo; therefore, LHRH analogue (LHRHa) was synthesized for improved stability and bioactivity to target LHRH receptor. 7 Compared to conventional protein macromolecules (LHRH), LHRHa peptides offer several advantages, including lower antigenicity, better stability, and easier preparation. Used as an active targeting ligand, LHRHa enables specific delivery of diagnostic or therapeutic drugs to LHRH receptor-positive cancer cells. 8,9 This approach significantly improves diagnostic or therapeutic efficacy, while substantially limiting adverse side effects on healthy tissues. 6,10,11 Several studies have suggested that the mechanism of LHRHa-modified drug delivery systems may be related to receptor-mediated endocytosis in LHRH receptor-positive cancer cells. 7,11 Furthermore, it has been reported that LHRHa-modified drug delivery systems show no toxicity to the pituitary and almost no influence on the concentration or reproductive functions of luteinizing hormone. 6 In summary, LHRHa emerges as a promising targeting ligand for targeted drug delivery systems to treat ovarian cancers. Integrin αvβ3 receptor is overexpressed on the surface of cancer cells, and RGD peptide can specifically bind to integrin αvβ3 receptor. RGD, as a targeting moiety, has been widely used in modified drug delivery systems (TDDS) -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology